Latest Research And Development News

333D Limited has responded to ASX queries, clarifying that its Bitcoin Treasury Management Policy approval is not price sensitive, while disclosing a $370,500 Bitcoin acquisition funded partly by R&D tax incentives.

4DMedical has bolstered its financial footing with a $6 million R&D tax incentive and a $10 million strategic investment, while its XV LVAS® technology gains clinical validation for predicting serious COPD treatment complications.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Netlinkz Limited has reported a significant 43% reduction in net loss for FY25, driven by a strategic exit from China and Japan and a renewed focus on cybersecurity growth in the Philippines through its Securelink Networks joint venture.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

FBR Ltd reported a 57% revenue increase driven by property sales but posted a $29 million loss as it advances commercialization of its Hadrian X® robotic bricklayer and secures significant new funding.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.